Skip to content
Screener

Aktis Oncology, Inc. AKTS Q1 2027 earnings

Reported November 12, 2026 · Before market open

Revenue$3.9MMiss by $968.5K
EPS-$0.54Miss by $0.07
Revenue estimate$4.9M
EPS estimate-$0.47
“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies. This substantial clinical progress is a testament to our ability to execute rapidly with quality across multiple clinical trials and positions Aktis for a data-rich 2027.”
Matthew Roden

Next report

Date not yet announced

FAQ

When did Aktis Oncology, Inc. report Q1 2027 earnings?
Aktis Oncology, Inc. (AKTS) reported Q1 2027 earnings on November 12, 2026 before market open.
What were Aktis Oncology, Inc.'s Q1 2027 revenue and EPS?
Aktis Oncology, Inc. reported revenue of $3.9M and eps of $-0.54 for Q1 2027.
Did Aktis Oncology, Inc. beat estimates in Q1 2027?
Revenue missed the consensus estimate of $4.9M by $968.5K. EPS missed the consensus estimate of $-0.47 by $0.07.
Where can I find Aktis Oncology, Inc.'s Q1 2027 SEC filings?
You can read the 8-K earnings release (0001193125-26-457045) and the 10-Q periodic report (0001193125-26-457054) directly on SEC EDGAR. The filing index links above go to sec.gov.